In a similar stroke model, ADT-OH reduced tissue plasminogen activator (tPA)-enhanced hemorrhage by inhibiting the protein kinase b/vascular endothelial growth factor/matrix metalloproteinase 9 (Akt/VEGF/MMP9) pathway (Table 2) [68]. The gene discussed is PTK2B; the disease is stroke disorder.